, /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient organization in the U.S., and Bayer were recently honored with the national 2024 Reuters Pharma Award in Driving Health Equity.
AAKP and Bayer were recognized for a new market-driven approach to patient engagement, clinical trial design, and diverse trial recruitment that accelerates kidney innovation and expands consumer choice of kidney health solutions. For Bayer, AAKP developed and engaged a Standing Patient Council that provided a systematic co-development approach to trial design, trial site selection, trial-related information and forms, and recruitment and retention strategies. The Standing Patient Council was representative of the diverse kidney disease population and their insights shaped tactics used to successfully enroll Black and Hispanic kidney patients at sustained levels that exceeded clinical trial expectations.
The AAKP and Bayer joint award submission was entitled " ." AAKP President , stated, "AAKP is very proud of the patients who participated in the Standing Patient Council and clinical trial as well as our shared recognition by Reuters with a 2024 Pharma Award. Our partnership with Bayer has been highly successful and we appreciate their ongoing commitment to kidney medicine and their sophisticated understanding of the longstanding unmet patient needs for advanced therapies to prevent, slow, and cure this devastating disease.
Together.
